SB9, developed by MSD in collaboration with Samsung Bioepis, is a biosimilar of Lantus developed by Sanofi.
Samsung Bioepis is an affiliate of Korean tech giant Samsung Electrioncs.
According to reports, SB9 could be approved for sale by the end of next year.
Including SB9, Samsung Bioepis has six biosimilar products in the works. Of the six, two treatments for autoimmune conditions have been approved in South Korea and Europe.
By Choi He-suk (firstname.lastname@example.org)